SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Fannie Lou Hamer

PatientFannie Lou Hamer
Date of birth1976-10-06
IdentifiersMRN HR-ML031-SYN; SSN (made up) 000-31-2479
Document date2026-10-19
AuthorLorraine Batiste-Hill, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Seven-month review: A1c, urine albumin, kidney function, seasonal and age-50 vaccines, screening results, and plans for the winter. [S]

History of Present Illness

Mrs. Hamer returns five weeks after her preventive visit; she turned 50 this month. Her mammogram two weeks ago showed no abnormality, and her stool test, HIV and hepatitis C tests were negative. She went to the mammogram with the community health worker and said the technologist explained every step. Her home readings average 126/78. She takes metformin 1,500 mg with her evening meal without stomach trouble and has had no low blood sugar. Food and heating are covered for the winter, and the van has brought her to every visit. She asked about the vaccines due this autumn and what each one is for. [S]

ElementDetail
ScreeningMammogram normal; stool test, HIV and hepatitis C negative
Home blood pressureAverage 126/78
Metformin1,500 mg, well tolerated
VaccinesInfluenza, COVID-19 and zoster discussed

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or weight gain
CardiovascularNegativeNo ankle swelling
GastrointestinalNegativeNo stomach upset
GenitourinaryNegativeNo burning or genital itching
PsychiatricNegativeMood steady

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin extended-release 500 mg oral tablet, one tablet with the evening meal for one week, then two tablets with the evening mealTwo tablets with the evening meal (after one week of one tablet)Oral route2026-03-09 to 2026-07-13completedS
Metformin extended-release 500 mg oral tablet, three tablets with the evening mealThree tablets with the evening mealOral route2026-07-13activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-09activeS
Amlodipine 5 mg and benazepril 20 mg combined oral capsule, one capsule dailyOne capsule dailyOral route2026-03-23activeS
Dapagliflozin 10 mg oral tablet, one tablet daily; stop on days of vomiting, diarrhea or not eating, and before surgeryOne tablet daily, with sick-day rulesOral route2026-03-23activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-19Body height163cmS
2026-10-19Body weight90kgS
2026-10-19Body mass index (BMI) [Ratio]33.9kg/m2S
2026-10-19Systolic blood pressure124mm[Hg]S
2026-10-19Diastolic blood pressure76mm[Hg]S
2026-10-19Heart rate74/minS
2026-10-19Respiratory rate16/minS
2026-10-19Body temperature36.7CelS
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-19Hemoglobin A1c/Hemoglobin.total in Blood6.9%Below 5.7% is normal; 6.5% or higher is diabetes; goal below 7% for herHighS
2026-10-19Albumin/Creatinine [Mass Ratio] in Urine41mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2)HighS
2026-10-19Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-10-19Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.59-1.04 mg/dLNormalS
2026-10-19Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M69mL/min/{1.73_m2}90 or higher is normal; 60 to 89 is mildly decreased (G2)LowS
2026-10-19Accountable health communities (AHC) health-related social needs screening (HRSN) tool1{score}S

Physical Exam

Vital signs recorded on 2026-10-19; see the Vital Signs section. [S]

SystemFinding
Consent and chaperoneEach vaccine, the blood draw, urine sample and examination explained and agreed; she accepted all three vaccines; female nurse present
GeneralWell; blood pressure 124/76, pulse 74; weight 90.0 kg
CardiovascularRegular rhythm; no ankle swelling
FeetInspected with her agreement: no ulcers

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes with hyperglycemia, newly diagnosed: A1c 8.6% and random glucose 238 mg/dL with thirst and frequent urination; synthetic modern episode linked to the diabetes documented in her later lifeactiveconfirmed E11.65S — Synthetic modern diagnosis; diabetes is documented only at the end of her life.
Elevated blood pressure at intake (164/98 mmHg), without a diagnosis of hypertension; home readings for one week to confirmresolvedconfirmed R03.0S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks.
Albumin in the urine (urine albumin-to-creatinine ratio 88 mg/g) and eGFR 73, in a woman whose kidneys were injured in a beating years ago; to be repeated and investigatedresolvedconfirmed R80.9S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks; the old kidney injury is documented.
Hypertension, stage 2, confirmed by home readings (average 152/94 mmHg), with chronic kidney disease; synthetic modern episode linked to the hypertension reported in her later lifeactiveconfirmed I12.9S — Synthetic modern diagnosis; hypertension is reported only at the end of her life.
Chronic kidney disease G2 A2 (eGFR 73, albumin-to-creatinine ratio 88 to 96 mg/g), with a small, scarred right kidney on ultrasound consistent with old injury; diabetes and high blood pressure likely contributeactiveconfirmed N18.2S — Synthetic kidney findings anchored to the documented permanent kidney damage.
Type 2 diabetes with diabetic chronic kidney disease (coded with the kidney disease by convention)activeconfirmed E11.22S — Synthetic modern coding.
Food insecurity: food runs out before the end of most monthsactiveconfirmed Z59.41S — Synthetic social need found on the screen.
Transportation insecurity: no car; the health center is a long drive away and rides are hard to arrangeactiveconfirmed Z59.82S — Synthetic social need anchored to her rural Delta home.
Hyperlipidemia: LDL 146 mg/dLactiveconfirmed E78.5S — Synthetic laboratory finding.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationConsent and chaperone for every examination, test and procedureEvery visitCompleted todayEach vaccine and test explained and agreed
ExaminationClinic blood pressure (seated, two readings, large cuff)Every visitCompleted today124/76
Self-managementHome blood pressure readingsSeven days to confirm the diagnosis; then twice a week, and daily for a week after any changeCompleted todayAverage 126/78
ExaminationWeight and BMIEvery visitCompleted today90.0 kg, down 3 kg since intake
LaboratoryHemoglobin A1cEvery 3 months until at goal, then every 6 monthsCompleted today6.9%
LaboratoryUrine albumin-to-creatinine ratioRepeat to confirm; 3 to 6 months after a treatment change; then every 6 months while moderately increasedCompleted today41 mg/g
LaboratoryPotassium, creatinine and eGFROne to two weeks after starting an ACE inhibitor, then every 6 months (more often with changes)Completed todayPotassium 4.5 mmol/L; creatinine 1.00 mg/dL, eGFR 69
LaboratoryLipid panel4 to 12 weeks after starting a statin, then yearlyUp to dateLDL 80 in May; yearly panel at one year
ImagingDiabetic eye examination (retinal photographs)At diagnosis, then every 1 to 2 years if no retinopathyUp to dateNo retinopathy in May
ExaminationFoot inspection, and comprehensive foot examinationInspection every visit; comprehensive examination yearlyCompleted todayInspection normal; comprehensive examination due at one year
LaboratoryVitamin B12 on metforminPeriodically, about yearlyDueAt the one-year visit
Medication safetyMedicine safety: low blood sugar, sick-day rules, genital infections, cough, swelling, adherence and costEvery visitCompleted todayNo side effects; 90-day supplies arranged for winter
Medication safetyInfluenza, COVID-19 and recombinant zoster vaccinesInfluenza and COVID-19 each autumn; zoster from 50, two doses 2 to 6 months apartCompleted todayAll three given after she agreed; zoster dose 2 in two to six months
SurveyDepression screen (PHQ-9)At intake, then every 6 to 12 monthsUp to datePHQ-9 3 three months ago; PHQ-2 0 at the preventive visit
SurveySocial needs screen (AHC-HRSN) and resourcesAt intake, then every few months while needs are openCompleted todayOne core need positive (transportation on some days)
ReferralNephrology reviewAt diagnosis; then by telehealth if albumin stays raisedDueTelehealth review in the new year because albumin remains moderately increased

Goal progress:

Immunizations given today: Influenza vaccine, inactivated, this season; COVID-19 vaccine, mRNA, this season; Recombinant zoster vaccine, dose 1 of 2 [S]

Guideline basis: Introduction and Methodology: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, diabetes type 2, hyperlipidemia, chronic kidney disease and depression monographs (2026); Trauma-Informed Care in Behavioral Health Services (Treatment Improvement Protocol 57) (2014); Code of Medical Ethics Opinion 2.1.1: Informed Consent (2026); The Accountable Health Communities Health-Related Social Needs Screening Tool (2017); Adult Immunization Schedule by Age (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Telehealth nephrology review in the new year. Review in three months, or by phone if travel fails; second zoster dose in two to six months. Call for dizziness, vomiting that stops her drinking, or any new symptom. [S]